gpi14 Antibody

What is GPI14 and why is it important in cellular biology?

GPI14 (also known as mannosyltransferase) is an essential enzyme in the glycosylphosphatidylinositol (GPI) biosynthesis pathway. It functions specifically for adding mannose on the glycosylphosphatidyl group during the synthesis of GPI anchors . The importance of GPI14 stems from its role in:

• Creating GPI anchors that tether over 150 different proteins to the cell surface

• Contributing to host-parasite interactions in infectious disease contexts

• Maintaining proper cell surface protein expression patterns

• Potentially serving as a drug target due to structural differences between mammalian and pathogen versions

The GPI pathway involves 26 genes and anchors at least 150 confirmed GPI-anchored proteins (GPI-APs) , which function as hydrolytic enzymes, receptors, adhesion molecules, complement regulatory proteins, and other immunologically important proteins implicated in various diseases .

What are the optimal sample preparation techniques for GPI14 antibody applications?

For optimal detection of GPI14, sample preparation varies by technique:

Western Blot:

• Cells should be lysed in buffer containing 1% Triton X-100 to solubilize membrane proteins

• Include protease inhibitors to prevent degradation

• Note that GPI-anchored GPI14 is often recovered from Triton X-100-insoluble fractions, while transmembrane forms are fully soluble

Flow Cytometry:

• For cell surface analysis: Wash cells twice with PBS, remove from culture dish with 2 mM EDTA

• Resuspend in FACS buffer (2 mM HEPES, 2 mM EDTA, 2% FCS in PBS)

• Filter through a 40-μm sieve for single-cell suspension

Immunoprecipitation:

• Preclear lysates with protein A-Sepharose beads

• For GPI14 complex studies, use native lysis conditions to preserve protein-protein interactions

How do GPI14 expression patterns vary across cell types?

Research has demonstrated significant variation in GPI14 expression patterns:

This differential expression is critical when selecting appropriate experimental models. Notably, in studies of pathogenic variants, fibroblasts showed reduced global GPI anchor levels while granulocytes maintained normal levels, suggesting that "fibroblasts might be more sensitive to pathogenic variants in GPI synthesis pathway and are well suited to screen for GPI-anchor deficiencies" .

How can GPI14 antibodies be used to study antimicrobial resistance mechanisms?

GPI14 has been implicated in antimicrobial resistance, particularly in parasites. Research methodologies include:

For Antimony Resistance Studies:

• Generate GPI14-overexpressing cell lines via transfection

• Confirm overexpression using quantitative real-time PCR (qRT-PCR) to measure mRNA levels

• Verify functional overexpression by measuring surface carbohydrates using concanavalin-A (Con-A) binding and flow cytometry

• Test antimony susceptibility by incubating cells with various antimony compound concentrations

• Use GPI14 antibodies for Western blot confirmation of protein expression levels

Research has shown that clones overexpressing GPI14 were 2.4- and 10.5-fold more resistant to potassium antimonyl tartrate (Sb III) than parental non-transfected lines, demonstrating that "GPI14 enzyme is implicated in the L. braziliensis Sb III-resistance phenotype" .

What approaches can be used to study GPI14's role in viral infection resistance?

Studies investigating GPI14's role in viral resistance employ several methodologies:

• Overexpression Studies:

  • Create plasmid constructs (e.g., pmCherryN1-GPI-MT-I)

  • Transfect target cells and confirm expression via fluorescent microscopy

  • Challenge with virus and measure viral loads at different timepoints

  • Use GPI14 antibodies for Western blot analysis to correlate protection with expression levels

• Expression Tracking During Infection:

  • Monitor GPI14 expression in tissues at intervals post-infection (0, 6, 12, 24, 48, and 72h)

  • Compare expression patterns between different tissues (spleen, kidney, cell lines)

  • Correlate expression patterns with viral load and pathology

Research has demonstrated that GPI14 mRNA expression is significantly upregulated following viral infection, with peak expression varying by tissue (12h in spleen, 6h in kidney, 48h in cell lines). Further, GPI14 overexpression significantly reduced viral gene copies and protein expression, suggesting that "GPI-MT-I might play a key role in the immune response against viral infection" .

How can researchers investigate GPI14's interactions with other proteins in the GPI biosynthesis pathway?

To study GPI14 protein-protein interactions:

• Co-immunoprecipitation:

  • Create tagged versions of GPI14 (e.g., GPI14-3FLAG or GST-GPI14)

  • Use anti-tag antibodies for immunoprecipitation

  • Analyze precipitated complexes via Western blot using antibodies against potential interaction partners

• Native PAGE Analysis:

  • Prepare cell lysates under non-denaturing conditions

  • Separate proteins on native gels to preserve complexes

  • Perform Western blot with GPI14 antibodies to identify higher-order complexes

• Yeast Two-Hybrid or Proximity Labeling:

  • Use GPI14 as bait to identify novel interaction partners

  • Confirm interactions with antibody-based techniques

Research has identified that GPI14 interacts with PBN1 to form a higher-order complex essential for mannosyltransferase activity. As noted in the Trypanosoma brucei studies, "TbGPI14 and TbPBN1 interact to form a higher-order complex" necessary for GPI-AP surface expression .

What are the optimal controls for GPI14 antibody validation?

For rigorous GPI14 antibody validation, include:

Positive Controls:

• Cell lines with confirmed GPI14 expression (HeLa, PC-3, U251, U87-MG cells)

• Overexpression systems with tagged GPI14 constructs

Negative Controls:

• GPI14 knockout cell lines (where viable)

• siRNA or shRNA knockdown samples

• Peptide competition assays to confirm antibody specificity

• Secondary antibody-only controls

Cross-Validation:

• Compare results using multiple antibodies targeting different epitopes

• Validate with orthogonal techniques (e.g., mass spectrometry)

• Match observed molecular weight (55-64 kDa) with predicted weight (63 kDa)

What experimental approaches can distinguish between GPI-anchored and transmembrane forms of proteins?

To distinguish between GPI-anchored and transmembrane proteins:

• Triton X-100 Solubility Assay:

  • GPI-anchored proteins localize to lipid rafts and are predominantly recovered from Triton X-100-insoluble fractions

  • Transmembrane proteins are typically fully soluble in Triton X-100

• Phosphatidylinositol-Specific Phospholipase C (PI-PLC) Treatment:

  • PI-PLC specifically cleaves GPI anchors

  • Compare protein localization or solubility before and after treatment

  • Measure released proteins in supernatant

• Flow Cytometry With Specific GPI Markers:

  • Use fluorescently labeled probes that specifically bind GPI anchors (e.g., FLAER)

  • Compare with antibodies against the protein of interest

  • Analyze co-expression patterns

Research has demonstrated that "like other GPI-anchored molecules, GPI-anchored CD14 was recovered mainly from a Triton X-100-insoluble fraction, whereas transmembrane CD14 was fully soluble in Triton X-100" .

How can researchers quantify changes in GPI-anchored protein expression following genetic manipulation of GPI14?

To quantify GPI-anchored protein expression changes:

Research has shown that cells transfected with GPI14 express "2.8-fold more mannose and glucose residues than the non-transfected or empty vector transfected lines, showing effective GPI14 overexpression" .

How can researchers address cross-reactivity issues when using GPI14 antibodies across different species?

When working with GPI14 antibodies across species:

• Epitope Analysis:

  • Align GPI14 sequences from target species to identify conserved regions

  • Select antibodies targeting highly conserved epitopes

  • Use bioinformatics tools to predict potential cross-reactivity

• Validation Strategies:

  • Test antibodies on positive controls from each species

  • Use knockout/knockdown controls when available

  • Perform peptide competition assays with species-specific peptides

• Optimization Approaches:

  • Adjust antibody concentrations (typically 1:500-1:2000 for WB, 1:100-1:400 for IHC)

  • Modify blocking conditions to reduce background

  • Try alternative detection methods or secondary antibodies

When possible, species-specific antibodies are preferable, but for cross-species studies, careful validation is essential.

What cell culture models are most appropriate for studying GPI14 function?

Selecting appropriate cell models is crucial for GPI14 research:

Recommended Cell Lines:

• THP-1 cells (human monocytic cell line) - Used successfully in GPI pathway studies

• HeLa cells - Confirmed GPI14 expression, good for transfection studies

• Fibroblasts - Show clear GPI-anchor deficiencies in pathogenic variants

• Organism-specific cell lines for parasite studies (e.g., L. braziliensis, T. brucei)

Experimental Considerations:

• Some phenotypes may be cell-type specific: "fibroblasts showed a reduced global level of GPI anchors and of specific GPI-linked markers" while "no significant differences in GPI-APs could be detected in patient granulocytes"

• For infectious disease studies, appropriate host-pathogen models are essential

• Primary cells vs. cell lines: primary cells often better reflect physiological conditions

Transfection Methods:

• Electroporation at 200V and 960 μF capacitance has been successfully used for THP-1 cells

• Selection with G418 (0.5 mg/ml) can establish stable transfectants

How can GPI14 research be applied to developing targeted therapies?

GPI14 presents several opportunities for therapeutic development:

• Antimicrobial Drug Targets:

  • GPI14 is "functionally different from that of the mammalian pathway"

  • "Structural variations in the side chain and lipid moiety between Leishmania and humans make GPI14 a rational drug target"

  • Researchers have developed "derivative compounds that were docked onto GPI14" to block biosynthesis

• HIV Resistance Strategies:

  • GPI-anchored inhibitors targeting HIV envelope proteins

  • Bifunctional constructs combining antibody fragments with fusion inhibitor peptides

  • "Cells modified by GPI-10E8 showing the most potent and broad anti-HIV activity"

• Cancer Therapeutics:

  • "GPI-APs and GPI pathway members as cancer biomarkers"

  • "Molecular targeting whether by blocking GPI-AP as a whole or by blocking members of GPI pathway"

The extensive involvement of GPI14 in multiple pathways makes it "a huge opportunity for molecular targeting... unlike other oncogenic proteins that have only few molecular targets" .

What are emerging technologies that could advance GPI14 research?

Several cutting-edge technologies hold promise for GPI14 research:

• CRISPR-Cas9 Gene Editing:

  • Generate precise knockout models to study GPI14 function

  • Create cell lines with tagged endogenous GPI14 for localization studies

  • Introduce specific mutations identified in patient populations

• Single-Cell Analysis:

  • Examine GPI14 expression heterogeneity within tissues

  • Correlate with GPI-anchored protein expression patterns

  • Identify cell subpopulations with unique GPI pathway characteristics

• Cryo-EM or X-ray Crystallography:

  • Determine GPI14 protein structure

  • Study GPI14-PBN1 complex formation

  • Design structure-based inhibitors

• Organoid Models:

  • Study GPI14 function in more physiologically relevant 3D systems

  • Examine tissue-specific effects of GPI pathway disruption

These technologies could help address remaining questions about "the regulation of GPI biosynthesis during virus infection [which] remains unclear and needs further investigation" .

How might systems biology approaches enhance our understanding of GPI14's role in cellular networks?

Systems biology offers powerful approaches to contextualize GPI14 function:

• Multi-omics Integration:

  • Combine transcriptomics, proteomics, and glycomics data

  • Map effects of GPI14 perturbation across multiple cellular systems

  • Identify unexpected pathway connections

• Network Analysis:

  • Position GPI14 within protein-protein interaction networks

  • Identify hub proteins that connect GPI pathway to other cellular processes

  • Predict effects of GPI14 modulation on downstream pathways

• Mathematical Modeling:

  • Develop kinetic models of GPI biosynthesis

  • Simulate effects of GPI14 alterations on GPI-AP expression

  • Predict therapeutic intervention points

• Comparative Genomics:

  • Analyze GPI14 evolution across species

  • Identify conserved functional domains and species-specific adaptations

  • Leverage evolutionary insights for drug development

These approaches could help resolve the challenge that "due to the lack of sufficient quantities of pure anchors and anchored proteins, it is difficult to study the characteristics and relationships among various glycosyltransferases during the synthesis of GPI-APs" .